Sanofi (SNY), a French pharmaceutical and healthcare company, Friday announced that it is executing the second tranche of its share ...

French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...

Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.

In 2024, we announced an intention to sell a controlling stake in Opella consumer health, which will make Sanofi (SNY ... such as rilzabrutinib in rare diseases and tolebrutinib in multiple ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to ... Genzyme has historically focused its efforts on rare inherited disorders, kidney ...

Ben Whitehouse, head of Rare Diseases, Sanofi UK and Ireland, stated: “At Sanofi, we’re committed to creating fulfilling futures for extraordinary people. No matter how rare their condition.

The Food and Drug Administration has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility in Massachusetts where the company makes ...

Sanofi‘s participation at the JP Morgan Healthcare Conference on January 14, 2025, was marked by a comprehensive overview of its position in 2024 and its strategic vision for the future. The CEO ...

French pharmaceutical giant Sanofi has received a warning letter from the U.S. Food and Drug Administration following an inspection at its drug manufacturing facility in Framingham. French ...

Sanofi's participation at the JP Morgan 43rd Annual Healthcare Conference on 14 January 2025 was marked by a comprehensive overview of the company's position in 2024 and its strategic vision for t ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...